A randomised trial comparing the efficacy of intraperitoneal (IP) drainage with or without intraperitoneal cisplatin for malignant ascites in gastrointestinal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN13223892

Enrollment

Registered

2002-08-19

Start date

1994-07-05

Completion date

Unknown

Last updated

2018-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oesophagus/stomach cancer Cancer Malignant neoplasm of other and ill-defined digestive organs

Interventions

Two arms: 1. IP drainage alone 2. IP drainage and IP cisplatin

Eligibility

Inclusion criteria

Inclusion criteria: 1. Histologically verified locally advanced or metastatic adenocarcinoma of the gastrointestinal tract 2. Clinically confirmed symptomatic ascites 3. Glomerular filtrate rate of >40ml/min 4. Patients must not have received intraperitoneal cisplatin before 5. No concurrent intravenous cisplatin, and at least a 2 week gap after the completion of intravenous cisplatin before intraperitoneal therapy can be commenced 6. Intravenous chemotherapy (except cisplatin) may be given concurrently 7. No medical contraindications to treatment

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
1. Toxicity 2. Ascites free survival 3. Time to ascites re-accumulation 4. Overall survival	—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026